The MLL-AF9 fusion gene is associated with aggressive leukemias of both the myeloid and lymphoid lineage in infants, whereas in adults, this translocation is mainly associated with acute myeloid leukemia. These observations suggest that differences exist between fetal and adult tissues in terms of the 'cell of origin' from which the leukemia develops. Here we show that depending on extrinsic cues, human neonatal CD34 þ cells are readily immortalized along either the myeloid or lymphoid lineage upon MLL-AF9 expression and give rise to mainly lymphoid leukemia in immunocompromised mice. In contrast, immortalization of adult bone marrow CD34
INTRODUCTION
Chromosomal translocations of the mixed lineage leukemia (MLL) gene on chromosome 11q23 are found in B7% of acute myeloid leukemia (AML) and 10% of acute lymphoid leukemia (ALL) cases. They are much more prevalent in therapy-related AML, and in infants, where they account for up to 80% of lymphoid and 50% of myeloid acute leukemias. 1 Infant ALL with MLL-rearrangements is associated with a particularly poor prognosis. 2 The very short latency of infant leukemias led to speculation that the initiating MLL-gene rearrangement occurs in utero in a cell of fetal origin. Evidence to support this hypothesis was provided by retrospective analysis of neonatal blood spots and twin studies of concordant infant MLL-rearranged leukemia. 3 Infant MLL-rearranged lymphoid leukemias often coexpress multiple myeloid markers 4 suggesting that the cell of origin in these leukemias is a hematopoietic stem cell (HSC) or lymphoid-myeloid progenitor cell. As HSCs possess inherent self-renewal capacity, additional genetic alterations that may be required for leukemogenesis would accumulate in this cell type and its progeny. Studies in mice have demonstrated that MLL-fusions can confer self-renewal activity to committed myeloid progenitors. 5, 6 Hence, a bipotential lymphoid-myeloid progenitor (which is active in murine fetal hematopoiesis) may also be the cell of origin in infant leukemias. 7 Importantly, immortalized and leukemogenic cells remained dependent on continued expression of the MLL-fusion protein suggesting that the MLL-fusion itself, or the genes which it regulates, are potential therapeutic targets. [8] [9] [10] Human models of MLL leukemias have also been developed. NOD-SCID mice transplanted with human umbilical cord blood (CB) cells expressing MLL-ENL developed ALL and cells expressing MLL-AF9 gave rise to ALL, AML or mixed lineage leukemia. 11 These findings led the authors to conclude that the MLL fusion partner has an instructive role in determining the lineage of the resultant leukemia as has been previously suggested. 12 However, another study demonstrated that MLL-AF9-expressing CB cells gave rise to AML exclusively in NOD-SCID mice transgenic for human myeloid cytokines. 13 This suggests that cytokines produced by the microenvironment in which the leukemic stem cell (LSC) resides have a dominant role in instructing lineage fate.
We hypothesized that intrinsic properties of the cell of origin may also have an important role in determining the lineage of the resultant leukemia. In adults, the MLL-AF9 fusion is predominantly associated with myeloid leukemias (in both de novo and therapyrelated cases) and very few lymphoid cases have been reported. In contrast, this fusion gene is found at a fairly similar frequency in pediatric leukemias of both the myeloid and lymphoid lineages. 14, 15 As infant leukemias are thought to originate from a cell of fetal origin, we investigated whether inherent differences exist between human neonatal and adult hematopoietic cells in terms of susceptibility to MLL-AF9-induced immortalization along the myeloid and lymphoid lineages. Indeed, we find that neonatal CD34 þ cells are readily immortalized along either the myeloid or lymphoid lineage upon MLL-AF9 expression, whereas immortalization of adult bone marrow (BM) CD34
þ cells is more difficult to achieve and is strongly myeloid-biased. Our observations faithfully recapitulate the phenotypes of pediatric and adult leukemias observed in patients with MLL-AF9 translocations and help to explain their high frequency in infants and therapy-related AML.
MATERIALS AND METHODS
Methods and Materials are included as Supplementary Information. Figure  S1B ). Whereas, FEIGW-transduced cells stopped growing after 1-2 months of culture, FEIGW-MLL-AF9 (F-MA) transduced CB and BM cells maintained a similar rapid proliferation rate for several months, although at late time points, the BM F-MA cultures showed signs of exhaustion ( Figure 1a ). Similar phenotypes were observed when the cells were co-cultured on MS5 (Figure 1b) . In one experiment, BM F-MA cells continued to expand beyond 3 months of culture at a rate comparable to the three CB F-MA cultures (Figure 1b) . However, in 2/3 experiments the BM F-MA cultures could not be maintained long term on MS5 stroma and the cells exhausted shortly after the second replating (Figure 1b) . This occurred despite the fact that cobblestone areas were still present underneath MS5 stroma in both the CB and BM F-MA cultures prior to the second replating ( Figure 1c) . The differential long-term growth capacity of the CB and BM F-MA cultures was not explained by differences in transduction efficiencies (Supplementary Figure S1C) , MLL-AF9 expression levels (Supplementary Figure S1D) or expression of known targets of MLL-fusion proteins including HOXA9, HOX10, MEIS1 and PBX3 (Supplementary Figure S1E) . LM-PCR indicated that all cultures displayed a similar level of clonality whereby one or two clones dominated the cultures after 4-6 weeks (Supplementary Figure S1F) .
RESULTS

MLL
In order to determine the myeloid progenitor activity of the co-cultures, GFP þ cells were harvested from co-cultures (experiment 2 in Figure 1b) at week 2 and plated in methylcellulose. The frequency of progenitors at this time-point was 6 times greater for CB than for BM cells expressing MLL-AF9 (Figure 1d ). Empty vector-transduced CB and BM cells did not form colonies in the second round of plating. However, CB F-MA cells were able to serially re-plate into subsequent rounds with increased frequency and the colonies displayed an immature appearance. Although BM F-MA cells formed some colonies in the second round, they were small with a differentiated appearance (data not shown) and were not able to re-plate into the 3rd round (Figure 1d ). Clonogenic assays in which GFP þ cells were harvested from stromal cocultures at week 3 and plated on new stroma at limiting dilution revealed that the clonogenic frequencies of CB F-MA þ cells were 31 times greater than BM F-MA þ cells (data not shown). Morphological analysis revealed that both the CB and BM F-MA cultures were composed of immature myelomonocytic cells. The BM F-MA cultures also contained some cells more differentiated along the monocytic lineage (Figure 1e ). In accordance with this, the BM F-MA cells expressed higher levels of the monocytic markers CD14 and CD11b than the CB F-MA cells (Figure 1f and Supplementary Figure S1G) . As both the CB and BM F-MA cells lacked CD34 and CD117 expression (Supplementary Figure S1G and data not shown), we attempted to identify a fraction enriched in clonogenic activity by isolating populations of cells based on CD15 and CD14 expression. As shown in Figure 1g , the CD15 À
CD14
À compartment of CB F-MA cultures was the most highly enriched for clonogenic activity, (1:30 ± 8) followed by the CD15 þ
À cells (1:80±20), whereas the CD15 þ CD14 þ and CD15 À CD14 þ cells displayed much lower clonogenic frequencies of 1:311 ( ± 88) and 1:370 ( ± 111) respectively. In line with these observations, only the CD15 À CD14 À BM F-MA cells were able to give rise to expanding cultures (Figure 1h ). Of note, the CD15 À
À cells were restricted to the myeloid lineage as the bulk myeloid cultures were CD33 þ and CD19 À (data not shown and Supplementary Figure S1G) Figure S2A) . Nevertheless, the cumulative CD19 þ progeny generated from CB cells was greater than that from BM (Supplementary Figure S2B) , indicating that their proliferative capacity was different under these conditions. Whereas, FEIGWtransduced cells proliferated only transiently, CB and BM F-MAtransduced cells continued to expand, although with different rates and durations (Figure 2a) . CB F-MA-transduced cells grew initially much faster than the BM F-MA-transduced cells and this proliferation rate was maintained for more than 4 months by which time the BM F-MA cells had exhausted ( Figure 2a ).
As these culture conditions promoted lymphoid as well as myeloid differentiation, suspension cells were analyzed at regular intervals for expression of lymphoid and myeloid antigens. After 3 weeks, distinct populations of cells that expressed CD19 or CD33 were observed (Supplementary Figure S2C) . The CD19 þ cells also coexpressed CD33, although typically at more intermediate levels compared with the CD33 single positive cells. The CD19 þ cells were classified as lymphoid as they displayed a lymphoid morphology (data not shown) and displayed higher levels of lymphoid gene expression (EBF1 and CD79A) and lower levels of myeloid gene expression (CSFR3 and CEBPA) than the myeloid cell lines (Supplementary Figure S2D) . The CD19 þ cells generated from MLL-AF9-transduced cells expressed much lower levels of CD20 than those generated from FEIGW cells, indicating a block in differentiation (Supplementary Figure S2C) . Lymphoid cells quickly dominated the CB F-MA cultures and within 3-5 weeks after plating, all of the cells were CD19 þ (Figures 2b and c; Supplementary Figure S2E ). These cells were capable of in vitro self-renewal as demonstrated by serial replating of the cultures (Figure 2a ). In contrast, the BM F-MA cultures were dominated by Figure S2E) . In all cases, the CD19 þ cells proliferated only transiently and lacked long-term self-renewal capacity, as CD19 þ cells were quickly lost after serial replating onto new stroma. LM-PCR analysis indicated that the CD19 þ cells were typically derived from a clone distinct from the myeloid cells that dominated the cultures initially (Supplementary Figure S2F) . Sequencing of lentiviral integration sites did not reveal insertion within or near known oncogenes, suggesting that integration site effects were unlikely to contribute to the observed phenotypes (Supplementary Table S1 ). Analysis of the CB and BM F-MA CD19 þ cells revealed that they shared a similar immunophenotype. Both 
À cell populations shown in panel F were isolated from the CB F-MA culture and plated in limiting dilution to determine clonogenic frequencies.
À cell populations shown in panel F were isolated from the BM F-MA culture and new myeloid MS5 cocultures were initiated with 100 000 sorted cells. The graph shows the total cumulative expansion of these sorted populations. populations expressed CD45RA but lacked expression of CD34 and CD20 (Supplementary Figure S2G) as well as of CD14 and CD15 (data not shown). The only apparent difference was the higher expression of CD33 by the CB F-MA cells.
The lymphoid immortalization defect of BM is intrinsic to the HSC compartment Several studies using murine models have shown that MLL-fusions are able to immortalize committed myeloid progenitors. 5, 18, 19 We demonstrated that human granulocyte-monocyte progenitors (GMPs) isolated from both CB and BM were susceptible to myeloid immortalization by MLL-AF9 (Supplementary Figure S3A) . Although the ability of MLL-AF9-transduced BM cells to proliferate long term under myeloid conditions was variable as observed previously using bulk CD34 þ cells (Figures 1a and b) , the variability existed between donors and not between GMPs and HSCs isolated from the same donor (Supplementary Figure S3A) . Q-RT-PCR showed that MLL-AF9 was overexpressed between 10-20 fold in these cells compared with the patient-derived cell line THP1 (Supplementary Figure S3B) . As both HSCs and GMPs may serve as the cell of origin in our model of MLL-AF9 AML, we reasoned that the myeloid immortalization bias of BM cells may be explained if BM has a higher frequency of myeloid progenitors than CB. Therefore, we analyzed the myeloid progenitor compartments of these tissues and found that BM had a lower
þ GMPs than CB (Figure 2d and Supplementary Figure  S3C) . Analysis of the lymphoid progenitor compartment revealed that BM had on average a 4-fold higher frequency of CD34
þ lymphoid progenitors, although this did not reach statistical significance (Figure 2d; Supplementary Figure S3C ). The analysis was repeated using a more stringent definition of lymphoid progenitors (Lin À CD34 þ CD10 þ and or CD7 þ ) but this did not change the relative difference in frequencies between the tissues (data not shown).
In order to investigate the possibility that inefficient lymphoid immortalization of BM CD34 þ cells was due to the enlarged BM-GMP compartment skewing transformation towards the myeloid lineage, we repeated the experiments using HSC-enriched
þ lymphoid progenitors. HSCs and lymphoid progenitors were sorted, transduced with FEIGW-MLL-AF9 or the empty vector and grown in lymphoid-permissive MS5 co-cultures. As shown in Figures 2e and f, lymphoid immortalization was readily achieved using MLL-AF9-transduced CB HSCs with kinetics comparable to bulk CD34 þ CB cells (Figure 2c ). In contrast, MLL-AF9-transduced BM HSCs gave rise to predominantly myeloid progeny for the first 10 weeks and the lymphoid cells that emerged at late time-points lacked long-term proliferative capacity (Figures 2e and f) . Immortalization of lymphoid progenitors was only achieved using neonatal cells; adult cells failed to proliferate under these conditions (Supplementary Figure S3D) . Although the majority of GFP þ cells generated from the neonatal lymphoid progenitors were CD19 þ (Supplementary Figure S3D) , the cumulative CD19 þ cell count was not as great as that generated from HSCs isolated from the same CB donor (Supplementary Figure S3E) . For example, after 29 days of culture, the yield of CD19 þ cells generated from HSCs was over 66 000 times greater than that generated from an equivalent number of lymphoid progenitors. This indicates that in experiments where total CD34 þ cells were transduced, the clones derived from HSCs likely dominated the lymphoid cultures after a few weeks.
Neonatal cells expressing MLL-AF9 give rise to AML or ALL in vivo The leukemogenic potential of MLL-AF9-transduced neonatal and adult CD34
þ cells was assessed in NOD/SCID or NSG mice.
Mice transplanted with empty vector-transduced cells remained healthy over the observation period studied. In contrast, all mice transplanted with MLL-AF9-transduced CB cells displayed increased numbers of GFP þ cells in the peripheral blood over time (Figure 3a) and developed a fatal leukemia with extensive infiltration of leukemic hCD45
þ GFP þ cells in the BM, spleen and liver (Figures 3b and c, Supplementary Table S2 ), which was serially transplantable to secondary recipients with a shorter latency (data not shown). The majority of the CB F-MA leukemic mice (4/6) developed ALL with a CD19
À phenotype, very similar to that of the immortalized lymphoid cell lines generated in vitro (Figure 3c , Supplementary Table S2 ) and to that previously reported. 13 However, one NSG mouse developed ALL after a long latency (178 days), perhaps due to the very low levels of engraftment of hCD45 þ cells in the peripheral blood at week 6 (Supplementary Table S3 ). The leukemic cells from this mouse displayed a more mature phenotype than the lymphoid leukemic cells from the other mice ( (Figure 3c, Supplementary Table S2 ), suggesting immortalization of a more mature, committed lymphoid progenitor or a less stringent differentiation block. One NOD/SCID mouse had both myeloid and lymphoid leukemia as distinct CD19
þ CD33 þ / À and CD19 À CD33 þ populations were observed (Figure 3c ). Flow sorting of these populations followed by LM-PCR indicated that each population was composed of a number of distinct clones that did not overlap, indicating that the myeloid and lymphoid leukemic cells in this animal were derived from different LSCs (data not shown).
Adult cells expressing MLL-AF9 give rise to long-term myeloid-biased engraftment in vivo but not leukemia In order to determine the leukemogenecity of adult cells expressing MLL-AF9, healthy BM or granulocyte colony-stimulating factor-mobilized peripheral blood (PB) were used as the source of adult CD34 þ cells. The yield of CD34 þ cells was much greater from mobilized PB than from BM and previous experiments had shown that MLL-AF9 was able to extend the proliferative capacity of PB cells grown in myeloid co-cultures in vitro (data not shown). In contrast to mice transplanted with MLL-AF9-transduced CB cells, mice transplanted with MLL-AF9-transduced BM or mobilized PB cells did not develop leukemia. It is likely that that lack of leukemia in mice transplanted with PB F-MA cells was due to a failure of these cells to engraft, as the percentage of human CD45 þ (hCD45 þ ) cells in the peripheral blood of both NOD/SCID and NSG mice 6 weeks after transplant was very low (Supplementary Table S3 ). However, the percentage of hCD45 þ cells in the peripheral blood of the BM F-MA-transplanted NSG mice at week 6 was comparable to that of the CB F-MAtransplanted NOD/SCID and NSG mice, indicating that the lack of leukemia in the BM F-MA mice could not be explained by differences in engraftment (Supplementary Table S3 ). Analysis of the BM F-MA-transplanted mice revealed long-term human engraftment in 2/3 mice and in both mice, GFP þ cells were observed (Figure 3d ). The long-term nature of this engraftment suggested that HSCs were transduced. Interestingly, in both mice, the majority of GFP þ cells were myeloid, whereas the GFP À cells were predominantly lymphoid (Figure 3d ). These data indicate that, in line with our in vitro observations, adult BM cells expressing MLL-AF9 are skewed towards the myeloid lineage in vivo.
Identification of lineage-specific, neonatal-specific and common MLL-AF9 gene signatures Neonatal cells immortalized by MLL-AF9 along the myeloid and lymphoid lineages displayed enhanced self-renewal capacity and leukemogenecity compared with adult cells. Genes changed specifically in the neonatal cells upon MLL-AF9 expression may provide insight into the mechanisms responsible for these phenotypes. Therefore, we performed gene expression profiling to identify a neonatal-specific and adult-specific MLL-AF9 gene signature. Our data set also enabled us to identify lineage-specific MLL-AF9 gene signatures and a common MLL-AF9 gene signature that was irrespective of lineage or tissue source. As shown in Figure 4a and Supplementary excel file 1, 1166 genes were differentially expressed in CB myeloid cells (430 up and 736 (Figure 4a ). Within this list, 23 genes were upregulated upon MLL-AF9 expression including previously described MLL-fusion target genes such as HOXA5, HOXA9, HOXA10, MEIS1 and PBX3 as well as several genes with no known role in MLL-rearranged leukemias including ZNF521, PRDM8 and IGF2BP2 (Figure 4b and Supplementary Figure S1E) . Although MLL-AF9 was unable to immortalize adult BM cells along the lymphoid lineage, we were able to isolate RNA from CD19 þ -sorted cells that could be generated, and we observed equal upregulation of the common targets HOXA9, HOXA10, MEIS1 and PBX3 (Supplementary Figure S1E) . These data indicate that the inability of MLL-AF9 to immortalize adult cells along the lymphoid lineage is not explained by an absence of MLL-AF9-induced expression of these common target genes. The Illumina expression data were validated by selecting a number of genes from the different MLL-AF9 gene signatures and examining their expression by Q-RT-PCR using samples from independent experiments (Figure 4c ). Expression data and potential function of genes in the common MLL-AF9 signature is summarized in Supplementary excel file 1.
Neonatal cells immortalized by MLL-AF9 share transcriptional programs with neonatal HSCs
To further interpret MLL-AF9 transcriptomes, we performed gene set enrichment analysis (GSEA). These analyses indicated that our MLL-AF9 gene signatures were enriched in genes that distinguish patients with MLL-rearrangements from other leukemia patients lacking MLL-rearrangements 20, 21 (Figure 4d ). Thus, our models of MLL-AF9 leukemias are physiologically relevant and our gene expression profiling approach is valid. Our neonatal and adult MLL-AF9 gene signatures correlated negatively with an adult stem cell signature 22 shared by BM HSCs as well as stem cells from the neural crest, hair bulge and mammary gland (Supplementary Figure S4A) . However, gene expression programs specific to both fetal and adult long term HSCs (LT-HSCs), 23 were significantly enriched in our neonatal and adult MLL-AF9 gene signatures (Supplementary Figure S4B) . Consistent with this, neonatal HSC expression programs 24 were significantly enriched within our myeloid and lymphoid neonatal MLL-AF9 gene signatures (Supplementary Figure S4C) . However, negative or nonsignificant correlations were observed between our adult MLL-AF9 signature and neonatal HSC-specific signatures identified by Jaatinen et al, 24 Novershtern et al 25 and Eppert et al 26 raising the possibility that our adult MLL-AF9 cells are more similar to adult than neonatal HSCs (Supplementary Figures S4C-E) . Similarly, our neonatal myeloid MLL-AF9 signature did not positively correlate with these neonatal HSC-specific signatures identified by Novershtern et al 25 and Eppert et al 26 ( Supplementary Figures S4D and E) . However, the neonatal lymphoid MLL-AF9 signature was consistently and significantly enriched for HSC-specific transcriptional programs despite differences in the methodologies used to generate the HSC-specific transcriptomes. This may suggest that the lymphoid MLL-AF9-expressing cells are more similar to HSCs than the myeloid cells. As HSCs and GMPs may serve as the cell of origin in our model of MLL-AF9 AML, we questioned whether our myeloid MLL-AF9 signatures were more akin to normal progenitors than HSCs. However, both the adult and neonatal MLL-AF9 gene signatures negatively correlated with gene expression programs specific to progenitors 25 and mature cells 23 (Supplementary Figure S4F ; Supplementary excel file 2) indicating that our MLL-AF9-expressing myeloid cells did not share transcriptomes with normal myeloid progenitors or myeloblasts.
Neonatal MLL-AF9 gene signatures are enriched in a MYC expression module and are associated with poor prognosis and resistance to chemotherapeutic agents Within the myeloid neonatal-specific MLL-AF9 signature, upregulated genes included BCL11a, BCL2 and SOX4. GSEA indicated that ESC-like gene expression programs (Wong et al 22 ) , which are shared by LSCs in a murine MLL-AF9 leukemia model, 27 were significantly enriched in neonatal but not in adult MLL-AF9 gene expression signatures (Figure 4e) . Recently, ESC signatures have been subdivided into a number of different modules including a 'PRC2 module', a 'MYC module' and a 'core ESC module'. 28 Analysis of these individual modules revealed that our MLL-AF9 gene signatures were not enriched for core ESC module genes, in line with previous studies 28, 29 (data not shown). In contrast, there was a strong positive correlation between MYC module genes as well as MYB signatures and the neonatal MLL-AF9 gene signatures (Figures 4f and g ). The myeloid neonatal MLL-AF9 gene signature was also significantly enriched for genes associated with poor prognosis pediatric AML (Figure 4h ) and doxorubicin resistance (Supplementary excel file 2) . In contrast, adult cells expressing MLL-AF9 were not enriched in genes associated with the MYC module, MYB signatures, poor prognosis AML or doxorubicin resistance.
DISCUSSION
Our models of MLL-AF9-mediated immortalization of neonatal and adult human CD34
þ cells closely parallel the phenotypes of infant and adult leukemias associated with the MLL-AF9 fusion. Infant leukemias, which originate in utero from a cell of fetal origin, are either myeloid or lymphoid in nature. Consistent with this, we found that neonatal CD34 þ CB cells were readily immortalized along either the myeloid or lymphoid lineage depending on extrinsic cues. In contrast, adult leukemias associated with this fusion gene are almost exclusively myeloid. Accordingly, we showed that immortalization of adult cells was skewed towards the myeloid lineage even under lymphoid culture conditions. We propose that these observations are explained by differences within the pool of HSCs and progenitors susceptible to MLL-AF9 immortalization in neonatal and adult tissues. As we found that human BM contains a higher frequency of GMPs than CB and we demonstrated that MLL-AF9 was able to immortalize human GMPs, we reasoned that the higher abundance of GMPs in BM These data suggest that intrinsic differences between the neonatal and adult HSC compartment account for their differing susceptibility to lymphoid immortalization.
In the mouse, discreet subsets of HSCs have been identified that differ in their lineage output. 30 Myeloid-biased, lymphoid-biased and balanced HSCs, which are capable of both myeloid and lymphoid reconstitution in irradiated recipients, have been reported. 31 Interestingly, a recent report found that the frequency of myeloid-biased HSCs was much lower in murine fetal liver than in adult BM. 32 If directly translated to the human setting, these data are compatible with our results. Transduction of myeloid-biased HSCs with MLL-AF9 would presumably skew immortalization towards the myeloid lineage that is indeed what we observe with adult cells. At late time-points, adult cells gave rise to lymphoid progeny in our in vitro assays, but these lymphoid cells were derived from a clone distinct from that of the myeloid cells that dominated the cultures initially, suggesting that the two clones were derived from distinct cells of origin. Alternatively, it is also possible that MLL-AF9 is not capable of activating the appropriate set of genes required for lymphoid immortalization in adult BM cells. Although future studies are required to reveal whether this hypothesis is true, we can exclude the possibility that the common HOXA5, HOXA10, MEIS1 and PBX3 genes are involved as these genes are upregulated by MLL-AF9 to comparable levels in lymphoid cells generated from CB and BM.
In addition to the different lineage bias of neonatal and adult cells upon MLL-AF9 expression, these cells appeared to differ in their susceptibility to MLL-AF9-mediated immortalization. MLL-AF9 efficiently immortalized neonatal cells in vitro and gave rise to ALL or both AML and ALL in vivo. In contrast, although MLL-AF9 expression extended the proliferative capacity of adult cells in vitro, immortalization was not readily achieved and varied substantially between BM donors. Consistent with this, mice transplanted with MLL-AF9-transduced BM or granulocyte colonystimulating factor-mobilized PB cells did not develop leukemia. The brief latency of leukemias in infants with MLL-rearrangements has fueled speculation that additional mutations are not required and that the MLL-fusion protein itself is sufficient for leukemogenesis. Although MLL-fusion proteins are powerful oncogenes, various mouse models have failed to model the short latency apparent in infants with this disease, suggesting that additional genetic or epigenetic events are required for leukemogenesis. 33, 34 We propose that fetal or neonatal cells are inherently more prone to immortalization by MLL-AF9 than adult cells and speculate that fetal/ neonatal cells may require fewer additional events than adult cells for leukemogenesis. A recent study reported that adult cells isolated from MLL-AF9 knockin mice gave rise to leukemia with a shorter latency than fetal cells. 35 The discrepancy between these results and ours include differences in the stage of ontogeny at which MLL-AF9 was expressed. We expressed MLL-AF9 'de novo' in neonatal and adult cells whereas MLL-AF9 expression was initiated during fetal development in the knockin model. Thus our model more faithfully reflects the leukemias observed in adults where a prenatal origin of disease is highly unlikely. Furthermore, we used a lentiviral vector to deliver MLL-AF9 to the target cells.
Owing to the difficulty in collecting sufficient amounts of BM cells from healthy individuals, our sample size was small. We cannot exclude the possibility that leukemia would have been achieved from adult cells if the number of mice per group was larger, if more cells were transplanted, or if more BM donors were used. Intrafemoral rather than intravenous injection may have also aided the development of leukemogenesis from adult cells. However, the engraftment levels of CB and BM cells 6 weeks after transplantation were similar, implying that the homing of these cells was not dramatically different. Furthermore, the transduction efficiencies, level of MLL-AF9 overexpression and initial myeloid in vitro expansion of CB and BM cells transduced with MLL-AF9 were comparable. All of the experiments performed using CB cells generated immortalized cell lines in vitro and induced leukemia in vivo. However, several of the adult cell lines exhausted at late time-points and were not capable of engrafting NSG mice (data not shown). Thus, based on our comparative in vitro and in vivo analyses, we conclude that fetal/neonatal cells are more efficiently transformed by MLL-AF9 than adult cells. We hypothesize that differences in the proliferative properties and self-renewal decisions of fetal and adult HSCs may be responsible for this. For example, fetal HSCs cycle rapidly undergo many symmetric self-renewal divisions, 36 yet adult HSCs are mostly quiescent and under homeostatic conditions undergo asymmetric divisions to ensure the maintenance of the HSC pool. Thus, it may be more demanding to transform a quiescent adult HSC than a rapidly cycling fetal HSC. An alternative explanation and one that is difficult to address is that the culture conditions and xenotransplantation model are limiting and do not fully support self-renewal and leukemogenesis from adult myeloid cells. MLL-AF9-transduced adult cells were myeloid biased and it is possible that the presence of a human niche providing human growth factors and cytokines is essential to allow full myeloid transformation. Recently, an elegant model in which NSG mice were injected with scaffolds coated with mesenchymal stem cells was described 37 and we are currently evaluating the transformation potential of neonatal versus adult MLL-AF9 transduced cells in this human niche NSG model.
Genes that were changed in both neonatal and adult cells upon MLL-AF9 expression included HOXA5, HOXA9, HOXA10, MEIS1 and PBX3. HOXA9 and MEIS1 have well described roles in both the induction and maintenance of MLL-fusion leukemias. [38] [39] [40] However, they were expressed at similar levels by neonatal and adult cells transduced with MLL-AF9, which implies that they are likely required but not sufficient for long-term self-renewal mediated by MLL-AF9, as previously suggested. 10 GSEA indicated that neonatal but not adult MLL-AF9 gene signatures were enriched in genes expressed in neonatal HSCs. This may indicate that long-term self-renewal and transformation involves maintenance or reactivation of neonatal HSC-specific programs. In accordance with this, LSCs isolated from primary AML patients were enriched in neonatal HSC transcriptional programs and the degree of enrichment was shown to correlate with poor prognosis. 26 We demonstrated that both human HSCs and GMPs are susceptible to myeloid transformation by MLL-AF9. Mouse models have demonstrated that MLL-AF9 LSCs most closely resemble a GMP or mid-myeloid lineage cell at both the phenotypic and molecular level. 18, 27 Interestingly, our human MLL-AF9 gene signatures were more similar to HSCs than GMPs. Our analysis was performed on bulk cultures without prior selection of cells based on phenotype or function. The seeming discrepancy between our data and the mouse models might simply reflect these differences. Nonetheless, our data is consistent with the finding from one of the mouse models in which a subset of HSC-specific genes were expressed in MLL-AF9 LSCs. This study revealed that MLL-AF9 is able to reactivate expression of HSC-specific genes in murine GMPs. 18 Infant leukemias harboring MLL rearrangements tend to have a particularly poor prognosis.
2 Consistent with this, neonatal MLL-AF9 gene signatures were significantly enriched in genes associated with poor prognosis AML-and doxorubicin resistance. Previous studies have highlighted the relationship between resistance to chemotherapeutic agents such as doxorubicin, and poor prognosis in AML. 41 The neonatal MLL-AF9 signature was also enriched in expression of a core MYC network. MYC has been shown to be a direct target of MLL-AF9 10 and MYC module activity was found to correlate with LSC frequency in a murine model of MLL-AF9 AML. 28 Furthermore, the differentiation arrest observed in murine stem and progenitor cells upon MLL-ENL expression was shown to be dependent on MYC expression. 42 As adult MLL-AF9-expressing cells were not enriched in MYC module activity, this may explain their more differentiated phenotype, poor clonogenic potential and lack of long-term self-renewal ability. Other candidate genes that are differentially expressed between neonatal and adult cells expressing MLL-AF9 and may cooperate in transformation include BCL11a, BCL2 and SOX4. BCL11a was recently shown to cooperate in MLL-AF9 leukemogenesis 43 and BCL2 has been implicated in the pathogenesis of MLL-rearranged leukemias. 44, 45 The oncogene SOX4, 46 an agonist of Wnt signaling that stimulates b-catenin activity, 47 is of particular interest since activated b-catenin is essential for self-renewal mediated by MLL-fusion proteins. 48, 49 Future experiments will determine whether coexpression of c-MYC and MLL-AF9 in adult cells enhances their transformation capacity.
In summary, we have shown that although cytokines have an instructive role in determining the lineage of cells transformed by MLL-AF9, intrinsic properties of the cell of origin also have an important role. We propose that the predominance of MLL fusions in infant leukemias reflects the fact that fetal or neonatal cells are inherently more prone to transformation by these fusions than adult cells.
